The DOI matches its Crossref record.
The Mechanism of Action of Cyclosporin A and FK506
Open accessAbstract
The immunosuppressants cyclosporin A (CsA), FK506, and rapamycin suppress the immune response by inhibiting evolutionary conserved signal transduction pathways. CsA, FK506, and rapamycin bind to their intracellular receptors, immunophilins, creating composite surfaces that block the activity of specific targets. For CsA/cyclophilin and FK506/FKBP the target is calcineurin. Because of the large surface area of interaction of the drug-immunophilin complex with calcineurin, FK506 and CsA have a specificity for their biologic targets that is equivalent to growth factor-receptor interactions. To date, all the therapeutic as well as toxic effects of these drugs have been shown to be due to inhibition of calcineurin. Inhibition of the action of calcineurin results in a complete block in the translocation of the cytosolic component of the nuclear factor of activated T cells (NF-AT), resulting in a failure to activate the genes regulated by the NF-AT transcription factor. These genes include those required for B-cell help such as interleukin (IL-4) and CD40 ligand as well as those necessary for T-cell proliferation such as IL-2. The purpose of this article is to illustrate the means by which these drugs produce immunosuppression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Calcineurin: Form and Function
Rusnak, F., & Mertz, P. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.4.1483 · Cited by 1,373
Mitochondrial permeability transition: a common pathway to necrosis and apoptosis
Kim, J.-S., He, L., & Lemasters, J. J. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00618-1 · Cited by 755
Dojcinov, S. D., Venkataraman, G., Raffeld, M., Pittaluga, S., & Jaffe, E. S. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181cf8622 · Cited by 571
Extracellular Matrix Molecules: Potential Targets in Pharmacotherapy
Järveläinen, H., Sainio, A., Koulu, M., Wight, T. N., & Penttinen, R. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001289 · Cited by 566
Onouchi, Y., Gunji, T., Burns, J. C., Shimizu, C., Newburger, J. W., Yashiro, M., Nakamura, Y., Yanagawa, H., Wakui, K., Fukushima, Y., et al. (2008) · Nature Genetics · doi:10.1038/ng.2007.59 · Cited by 510
Regulation of Cell Cycle Progression by Calcium/Calmodulin-Dependent Pathways
Kahl, C. R., & Means, A. R. (2003) · Endocrine Reviews · doi:10.1210/er.2003-0008 · Cited by 496
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Sbidian, E., Chaimani, A., Garcia-Doval, I., Do, G., Hua, C., Mazaud, C., Droitcourt, C., Hughes, C., Ingram, J. R., Naldi, L., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011535.pub2 · Cited by 433
Targeting mammalian target of rapamycin (mTOR) for health and diseases
Tsang, C. K., Qi, H., Liu, L. F., & Zheng, X. F. S. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.12.008 · Cited by 406
The Transcription Factor NF-ATc1 Regulates Lymphocyte Proliferation and Th2 Cytokine Production
Yoshida, H., Nishina, H., Takimoto, H., Marengère, L. E. M., Wakeham, A. C., Bouchard, D., Kong, Y.-Y., Ohteki, T., Shahinian, A., Bachmann, M., et al. (1998) · Immunity · doi:10.1016/s1074-7613(00)80464-1 · Cited by 339
Self-citationAltered neural connectivity in excitatory and inhibitory cortical circuits in autism
Zikopoulos, B., & Barbas, H. (2013) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2013.00609 · Cited by 313
Kim, J.-S., Jin, Y., & Lemasters, J. J. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00683.2005 · Cited by 310
Comprehensive review of cardiovascular toxicity of drugs and related agents
Mladěnka, P., Applová, L., Patočka, J., Costa, V. M., Remiao, F., Pourová, J., Mladěnka, A., Karlíčková, J., Jahodář, L., Vopršalová, M., et al. (2018) · Medicinal Research Reviews · doi:10.1002/med.21476 · Cited by 310
Seggewiss, R. (2005) · Blood · doi:10.1182/blood-2004-07-2527 · Cited by 290
Roberts, M. B., & Fishman, J. A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1189 · Cited by 277
Potent Synergism of the Combination of Fluconazole and Cyclosporine in Candida albicans
Marchetti, O., Moreillon, P., Glauser, M. P., Bille, J., & Sanglard, D. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2373-2381.2000 · Cited by 252
Nkongolo, S., Ni, Y., Lempp, F. A., Kaufman, C., Lindner, T., Esser-Nobis, K., Lohmann, V., Mier, W., Mehrle, S., & Urban, S. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.022 · Cited by 255
Hughes, S. J., & Ciulli, A. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170041 · Cited by 240
Park, H.-S., Lee, S. C., Cardenas, M. E., & Heitman, J. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.08.004 · Cited by 168
“CsA and FK506 bind to the immunophilins cyclophilin A and FKBP12, respectively, and each complex blocks access of the target proteins to the active site of calcineurin (Ho et al., 1996).”
BackgroundJuvvadi, P. R., Lamoth, F., & Steinbach, W. J. (2014) · Fungal Biology Reviews · doi:10.1016/j.fbr.2014.02.004 · Cited by 116
Marchetti, O., Entenza, J. M., Sanglard, D., Bille, J., Glauser, M. P., & Moreillon, P. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.11.2932-2938.2000 · Cited by 113
Drug nanocarriers to treat autoimmunity and chronic inflammatory diseases
Prosperi, D., Colombo, M., Zanoni, I., & Granucci, F. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.010 · Cited by 106
“The most common commercially available drugs used to control undesired immune responses, such as Cyclosporin A or Rapamycin [19,20], usually require chronic administration.”
Reedy, J. L., Filler, S. G., & Heitman, J. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.09.002 · Cited by 76
Juvvadi, P. R., Gehrke, C., Fortwendel, J. R., Lamoth, F., Soderblom, E. J., Cook, E. C., Hast, M. A., Asfaw, Y. G., Moseley, M. A., Creamer, T. P., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003564 · Cited by 57
Activation of Lyn, Blk, and Btk But Not Syk in CD72-Stimulated B Lymphocytes
Venkataraman, C., Muthusamy, N., Muthukkumar, S., & Bondada, S. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.7.3322 · Cited by 52
Ong, S., Levy, R. D., Yee, J., Partovi, N., Churg, A., Roméo, P., Chalaoui, J., Nador, R., Wright, A., Manganas, H., et al. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0727-0 · Cited by 18
Juvvadi, P. R., Ma, Y., Richards, A. D., Soderblom, E. J., Moseley, M. A., Lamoth, F., & Steinbach, W. J. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00175 · Cited by 17
Metadata
- Authors
- Ho, S., Clipstone, N., Timmermann, L., Northrop, J., Graef, I., Fiorentino, D., Nourse, J., & Crabtree, G. R.
- Venue
- Clinical Immunology and Immunopathology
- Publisher
- Elsevier BV
- Published
- 1996-09
- Volume
- 80
- Issue
- 3
- Pages
- S40-S45
- ISSN
- 0090-1229 (ISSN-L)
- OpenAlex
- W1984947099
- Cited by
- 677
- References
- 0
- FWCI
- 7.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.